Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11241377 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
US11173110 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
US11007139 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
US10195138 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
US10182982 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
US11759416 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
US11752094 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
US10085936 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
US10881605 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
US10058504 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
US10463607 | LABS FARMS ROVI SA | Antipsychotic Injectable Depot Composition |
May, 2031
(6 years from now) | |
US11752093 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
US10335366 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
US11752092 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 29, 2027 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 29 March, 2024
Treatment: Intramuscular administration of risperidone in extended release injectable suspension for treatment of schizophrenia in adults; Administration of risperidone in extended release injectable suspension ...
Dosage: FOR SUSPENSION, EXTENDED RELEASE